ClearPoint Neuro (CLPT)

Its flagship platform is associated with MRI-guided neurosurgery, where real-time imaging can support accurate targeting in delicate areas of the brain. ClearPoint’s products are used in procedures such as biopsy, catheter placement, laser ablation support, and delivery of therapeutic agents. The company’s technology is designed to improve procedural control while reducing the need for more invasive surgical approaches.

ClearPoint Neuro’s business has two closely related areas. The first is its medical device business, which supplies systems, disposable products, and services for neurosurgical applications. The second is its biologics and drug delivery partnerships business, where the company works with life sciences companies developing gene therapies, cell therapies, and other treatments that may require precise delivery into the brain or central nervous system.

This combination gives ClearPoint exposure to both hospital-based neurosurgery and the expanding field of targeted neurological therapeutics. Its role is not typically to create the drug or biologic itself, but to provide the enabling technology and procedural expertise that can help deliver these therapies to the intended location.

The company operates in a specialised medical market where adoption depends on clinical evidence, regulatory requirements, hospital purchasing decisions, physician training, and the progress of partner therapy programmes. Its distinctiveness lies in combining navigation hardware, software, disposables, and procedural support for complex brain interventions.